Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912160 | 0.91 | SIGMAR1 (0.38) | OPRM1OPRL1SIGMAR1BACE1 | |
| 3-[2-(4-Hydroxy-Phenyl)-Ethyl]-5-Methyl-5-Phenyl-4,5-Dihydro-Isoxazole (Enantiomeric Mix) SCHEMBL2920444 | 0.90 | ESR1 (0.38) | ITGB1ITGA4OPRM1OPRL1SCN9A | |
| SCHEMBL14884947 | 0.83 | TDP1 (0.38) | SCN9AKCNH2SIGMAR1 | |
| 3-[3-(4-Hydroxy-Phenyl)-Propyl]-5-Methyl-5-Phenyl-4,5-Dihydro-Isoxazole (Enantiomeric Mix) SCHEMBL2915705 | 0.82 | CALM1 (0.37) | SCN9ASIGMAR1 | |
| SCHEMBL14168752 | 0.82 | ITGB1 (0.40) | ITGB1ITGA4KCNH2BACE1 | |
| SCHEMBL2740913 | 0.73 | KDM4E (0.43) | OPRM1OPRL1SCN9ABACE1 | |
| SCHEMBL679659 | 0.73 | KDM4E (0.43) | OPRM1OPRL1SCN9ABACE1 | |
| SCHEMBL12595265 | 0.71 | BACE1 (0.39) | SCN9ABACE1 | |
| SCHEMBL14028657 | 0.71 | ACHE (0.40) | ITGB1ITGA4OPRM1KCNH2SIGMAR1 | |
| SCHEMBL5011048 | 0.70 | TSHR (0.37) | ITGB1ITGA4OPRM1KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278942-B2 | Non-steroidal compounds as androgen receptor modulators | FLX DISCOVERIES OY (FI) | 2016-03-08 | — | — | US | disclosed |
| US-9278942-B2 | Non-steroidal compounds as androgen receptor modulators | FLX DISCOVERIES OY (FI) | 2016-03-08 | — | — | US | disclosed |
| US-9278942-B2 | Non-steroidal compounds as androgen receptor modulators | FLX DISCOVERIES OY (FI) | 2016-03-08 | — | — | US | disclosed |
| US-20140275186-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | FLX DISCOVERIES OY (FI) | 2014-09-18 | — | — | US | disclosed |
| US-20140275186-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | FLX DISCOVERIES OY (FI) | 2014-09-18 | — | — | US | disclosed |
| US-20140275186-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | FLX DISCOVERIES OY (FI) | 2014-09-18 | — | — | US | disclosed |
| WO-2013057372-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | PULKKINEN JUHA (FI) | 2013-04-25 | — | — | WO | disclosed |
| US-20100267784-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-10-21 | — | — | US | disclosed |
| US-20100267784-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-10-21 | — | — | US | disclosed |
| US-20100267784-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-10-21 | — | — | US | disclosed |
| EP-2222653-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | Pulkkinen, Juha (FI) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009066009-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA (FI) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009066009-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA (FI) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267784-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | ESR2, GPER1, CYP19A1 | ITGB1 3353/4885ITGA4 1259/4885OPRM1 524/4885 |
| US-20140275186-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, SHBG | ITGB1 2547/4885ITGA4 1932/4885OPRM1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.